AbbVie Tops Q1 Estimates, Raises Outlook and Discontinues Cancer Candidate

Why It Matters

The earnings beat and raised guidance underscore AbbVie’s ability to sustain growth beyond its legacy immunology franchise, while strategic pipeline investments signal a shift toward diversified, high‑margin oncology assets.

Key Takeaways

• Q1 revenue hit $15 billion, up 12.4% YoY
• Immunology sales rose 16.4% to $7.29 billion
• Neuroscience revenue jumped 26% to $2.87 billion
• Raised 2026 EPS guidance to $14.08‑$14.28 per share
• Stopped ABBV‑101 trial; added PD‑1/VEGF and KRAS deals

Pulse Analysis

AbbVie’s Q1 performance highlights a rare blend of organic growth and strategic execution. Revenue climbed to $15 billion, propelled by a 16.4% rise in immunology sales and a 26% jump in neuroscience, where Qulipta’s strong uptake lifted the segment to $2.87 billion. The earnings beat reassured investors, nudging the stock up modestly in pre‑market trading despite a 10% year‑to‑date decline, and prompted the company to raise its 2026 adjusted EPS guidance to a range of $14.08‑$14.28.

Beyond the headline numbers, AbbVie is reshaping its pipeline to reduce reliance on legacy drugs. The firm halted development of the BTK degrader ABBV‑101, citing strategic realignment rather than trial outcomes, and redirected resources toward more promising oncology candidates. In January, AbbVie secured exclusive rights to RemeGen’s PD‑1/VEGF bispecific antibody for $650 million upfront and up to $4.95 billion in contingent payments, positioning itself in a competitive bispecific market alongside BMS, Merck and Pfizer. A parallel agreement gives AbbVie an early‑stage KRAS inhibitor from Kestrel Therapeutics, with a total potential value of $1.45 billion, expanding its reach into solid‑tumor therapies.

The combined financial strength and pipeline diversification underpin AbbVie’s long‑term growth narrative. CEO Robert Michael emphasized a disciplined M&A approach, targeting assets that complement core areas—immunology, neuroscience, oncology, and obesity—while maintaining flexibility to pursue external innovation. By bolstering its oncology portfolio and maintaining robust cash flow, AbbVie aims to deliver sustained revenue expansion into the 2030s, offering investors a clearer line of sight to future earnings despite short‑term market‑share pressures in its immunology franchise.